TCM
KERX

Traynor Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Traynor Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,500
Closed -$55K – 142
2016
Q3 		$55K Buy
+12,500
New +$67.4K 0.04% 123

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Traynor Capital Management's KERX Position: Q4 2016 in Review

Traynor Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2016, closing a stake of 12,500 shares — an estimated $55K sold.

Traynor Capital Management first reported a position in KERX in Q3 2016 and held it in 1 quarter. The position peaked at $55K in Q3 2016. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

  • Traynor Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Traynor Capital Management sold 12,500 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $55K.
  • Traynor Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Traynor Capital Management's Keryx Biopharmaceuticals Inc position peaked at $55K in Q3 2016.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on Traynor Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.